written by reader Oxford Club’s Mark Litchfield’s teaser on Lighting Trend Trader.

by xiexgp | June 2, 2014 10:42 am

Is there really a way for anyone to get information on the FDA[1]’s announcements on their approval or disapproval for drugs? That to me sounds like insider stuff, what do you think
Lou Pre32

Endnotes:
  1. FDA: https://www.stockgumshoe.com/tag/fda/

Source URL: https://www.stockgumshoe.com/2014/06/microblog-oxford-clubs-mark-litchfields-teaser-on-lighting-trend-trader/


40 responses to “written by reader Oxford Club’s Mark Litchfield’s teaser on Lighting Trend Trader.”

  1. Observer says:

    I subscribe to Marc Lichtenfeld’s “Lightning Trend Trader” service, and I haven’t seen any evidence that Marc actually claims to have “insider” information. If he does have such access, he’s certainly using it to very poor affect. Prime example: He recommended puts on MannKind back in March, because he was virtually certain the FDA would reject one of its drugs, and then wrote that he was “stunned” when an FDA committee voted to approve the drug in April – the puts expired worthless. I posted the following elsewhere on Stock Gumshoe today:
    My impression is that Marc Lichtenfeld of Oxford Club is a smart guy and works hard – but my advice is to be very careful about subscribing to one of his “premier” services. So far this year, in his “Lightning Strike” service he has had the following results:
    Recommendation #1 stock – currently up 25%
    #2 stock – sold for a loss (price dropped and hit its 25% sell stop)
    #3 stock – sold for a loss
    calls – sold for a loss
    #4 puts – 100% loss
    #5 stock – sold for a loss
    #6 stock – sold for a loss
    #7 puts – presently down – 70%
    #8 stock – sold for a loss
    calls – sold for a loss
    #9 stock – currently up + 6%
    #10 stock – currently up + 2%
    calls – essentially even (depending on entry price)
    #11 stock – down 2%
    calls – down 17% below recommended entry limit

    And yet this “service” is being VERY heavily hyped right now by Oxford Club and Marc. To quote Marc: “The people who act on my recommendations are doing exceptionally well.” That might have been true last year – I gather it was, though his “service” was then called “Healthcare Profits Alert,” which apparently attracted few subscribers – but his results over the last 4 months don’t even remotely match up to that. Yet he says “people…are doing” (present tense) exceptionally well – which is just pure nonsense.
    I’m not sure why this type of thing doesn’t actually cross the line into illegal false advertising – his “present” results certainly don’t qualify as “exceptionally well” under any usage of the English present tense. (I sent Marc a note asking why he didn’t at least wait until he had one result – one single result – that merited the hype before launching an aggressive marketing campaign – no response.) I think these guys (in the newsletter business) are lucky they seem to fall under SEC scrutiny (but very very rarely) rather than the FTC – which it seems like they should since they’re marketing a “product.”
    Clear case of buyer beware…. The warning “past performance is no guarantee of future results” has never been truer.

  2. Alison says:

    I also would like to know why it is legal to state that the service has had 100% gains every 4 months in the year he has been doing this. He charts company after company that he predicted correctly.

  3. ecraig says:

    Found this post from Observer useful info. Does anyone have insights on the most recent Lichtenfeld promo of 3 bio techs? My summary below:
    Mark Lichtenfeld is promoting with Oxford Club his ‘Lightening Trend Trader’ strategy for a $1495 VIP service. His ‘lightening strike’ is a catalytic event driving average 100% growth every 4 months, mainly bio techs. Currently, he is promoting 3 opportunities to entice new subscribers:
    First is a $6 billion California-based ‘team player’ (collaboration agreements with AstroZenica, Biogen, Bristol Meyers Squib, Eli-Lilley, ..Genzyme and GlaxoSmithKline), and a pipeline of 28 cardiovascular, neurological and metabolic diseases, as well as cancer,
    Second is his ‘home run play’, a small-cap lung and liver cancer treatment company with ‘incredibly positive clinical phase results’, which recently began phase 3 trials on its catalyst – a colorectal cancer treatment which has ‘already happened’, promising a doubling or 200% or more….
    The third promoted company is a California company with ‘182’ staff, revolutionizing how our bodies fight cancer. Purportedly, Institutional investors like Blackrock and Vanguard have taken ‘big’ positions.
    The promo finishes by holding out the promise of a $973 million company with more clinical drugs in development ‘than you can imagine’, expected to triple.
    It would be nice when the Gumshoe sleuth returns from holidays, to hear what he thinks of the Lichtenfeld performance record, and whether he can tease out some of these firms awaiting their ‘lightning strike’.

  4. JEN says:

    Many thanks to Observer for a very useful post. I’ve learned to avoid any service that advertises great results but will not state a verifiable trading record outright (i.e. number of recommendations, actual recommended dates in and out and real gain/loss for each). It would have been very little additional effort for Mr. Lichtenfeld to simply state “I made x number of recommendations in 2013 with “y” losers and “z” winners” followed by a graphic of the actual recommendations/results…if the presentation was honest. In the scramble to obtain subscribers in the financial newsletter industry, folks with something to hide will generally only tout their winners and do their best to hide their actual trading record while implying something that isn’t supported by fact. I don’t recall Mr. Lichtenfeld even once mentioning a loss in his presentation. This nebulous 100.1 percent “average” which he touts over and over is a type of statistical manipulation often used to disguise the truth. I think he mentioned one options trade with a 775% return as well as multiple additional triple digit winners well in excess of 100% yet he averaged a 100% return overall. I can only conclude, in the absence of additional data, he had more losers than winners in 2013 and based on Observers experience, I’d say things have gone from bad to (much) worse for Mr. Lichtenfeld in 2014. There are many additional ways to manipulate the stats to hide reality. I can’t say for sure that Mr. Lichtenfeld is employing them but based on the results Observer experienced and the way in which Mr. Lichtenfeld presents his case, I wouldn’t bet against it. Suffice to say (my opinion) the spectacular returns Mr. Lichtenfeld touts are largely smoke and mirrors and most who sign up for his newsletter will not see results like that. Observer’s advice is solid. I would stay away from this “service.”

  5. Alan Harris says:

    Observer: Im not sure if your’e an Irregular (a whole $49 and the best you will ever spend!!) Look at the KSS bio threads. Never mind lightening, this is pure gold!!
    http://www.stockgumshoe.com/2014/07/the-gain-from-pain-mainly-explained-part-one/

  6. Alan Harris says:

    Hi Thomas….you are MOST welcome here. I look fwd to your comments on KSS threads (but until he knows your credentials, he can be a little ‘dismissive’). Can I suggest you cut and paste this comment there. Im sure he keeps a villians list and feel you will be on the white list. 🙂

  7. Observer says:

    Thomas: Found your comments interesting and informative – if only Oxford Club advertised its premium services something like that, which of course they don’t. It’s of course not really a “defense” of Marc Lichtenfeld in the context of this thread, which is specifically about his Lightning Trend Trader service – in which his results have been truly woeful (or at least as of 2 July when I cancelled and got a refund). He completely missed it on MannKind, Tekmira, Synergy, and others – and had his subscribers out of GW Pharma for like a 5% gain not too long before it doubled in value. Not exactly the results of someone investors should want to pay good money for stock advice – in this service at least. Personally, the fact that Marc continued to hype his LTT service ad nauseam based on last year’s results was/is a disgrace (same thing for Alex Green in his True Value service). But, I know full well how these things go. I still subscribe to three Oxford Club services, and have been involved with Oxford Club off and on for about 14 years. But I still find the advertising of their premium services nauseating – and, frequently, completely misleading. Just the nature of the business, unfortunately. (As a prime example, I closely followed Porter Stansbury’s conviction for fraud, which he appealed up to the Supreme Court and lost.)

  8. aye says:

    im new to investing with real money-on-the-line. anyone here have comment/experience with alex greens’ “golden cross” investment method?
    i had heard something of this technique years ago as being popular in the orient- i never tried it, and now find it here- offered a-la alex green. what say you experienced/knowledgeable folk?

  9. Otto Schlemder says:

    Somehow I made a mistake subscribing to the Lightning Trend Trader. The Oxford income letter subscription is OK. Is it possible to cancel The Lightning Trend Trader and get the $749.00 US refunded?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.